FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365514100> ?p ?o ?g. }

• W4365514100 endingPage "CT016" @default.
• W4365514100 startingPage "CT016" @default.
• W4365514100 abstract "Abstract Background: Fibroblast growth factor receptor (FGFR) alterations are promising targets in different tumors. We report results of FIGHT-207, an open-label, single-arm phase 2 study of pemigatinib, a potent, selective FGFR1-3 inhibitor, in patients with previously treated unresectable or metastatic FGFR-altered solid tumors (NCT03822117). Methods: Patients were assigned to cohorts A (FGFR1-3 fusions), B (FGFR1-3 activating non-kinase domain mutations), and C (FGFR1-3 kinase domain mutations and alterations of unknown significance) and received continuous 13.5 mg pemigatinib once daily. Prior FGFR inhibitor treatment was prohibited. The primary endpoint was objective response rate (ORR) per RECIST v1.1 or RANO as confirmed by independent central review. Results: 107 patients were enrolled and assigned to cohorts A (n=49), B (n=32), and C (n=26). ORR in cohorts A, B, and C was 26.5%, 9.4%, and 3.8%, respectively. Responses were observed for multiple tumor types, including gliomas and gynecologic and pancreatic tumors (Table). Notably, we saw responses for several infrequent FGFR alterations, including an FGFR1 kinase domain mutation (K656E) and an FGFR2 extracellular in-frame deletion (FGFR2 I291_Y308Del). Among patients in cohorts A+B with centrally confirmed FGFR alterations, BAP1 co-alterations were observed in 47% (7/15) of responders, and TP53 co-alterations were present in 43% (23/53) of nonresponders. Safety was consistent with prior reports. Conclusions: In addition to cholangiocarcinoma, pemigatinib showed clinical activity in gliomas, gynecologic tumors, and pancreatic cancer and safety was consistent with prior reports. We observed responses in patients with previously unreported FGFR alterations, suggesting that a broader population of patients may benefit from FGFR inhibitors. Further correlative work to predict response to therapy is needed to better identify these patients. Table. Characteristics of Patients With Best Percentage Change From Baseline in Target Lesion Size ≥30% Patient Tumor Type FGFR alteration* BOR Best % Change From BL in Target Lesion Size PFS, mo Gliomas 1 Glioblastoma FGFR3 fusion CR −100.0 20.2† 2 Glioblastoma FGFR3 fusion PR −100.0 8.4† 3 Diffuse astrocytoma FGFR1 K656E mutation PR −80.7 8.0 Gynecologic 4 Cervical cancer FGFR3 fusion PR −100.0 6.4 5 Cervical cancer FGFR3 fusion PR −32.1 6.3 6 Endometrial cancer FGFR1 rearrangement SD −100.0 1.9† 7 Ovarian cancer FGFR2 fusion SD −44.0 2.1† 8 Cervical cancer FGFR2 C382R mutation SD −35.6 5.6 Pancreatic 9 Pancreatic adenocarcinoma FGFR2 fusion PR −72.1 8.4† 10 Pancreatic adenocarcinoma 2 FGFR2 fusions PR −54.9 8.9† 11 Pancreatic adenocarcinoma FGFR2 fusion PR −33.3 6.3† 12 Pancreatic adenocarcinoma FGFR2 fusion SD −100.0 2.7 Cholangiocarcinoma 13 Cholangiocarcinoma FGFR2 fusion PR −64.6 6.2 14 Cholangiocarcinoma FGFR2 fusion PR −61.4 9.9 15 Cholangiocarcinoma FGFR2 fusion PR −53.5 8.8 16 Cholangiocarcinoma FGFR2 C382R mutation PR −49.7 6.0 17 Cholangiocarcinoma FGFR2 fusion PR −46.2 5.9† 18 Cholangiocarcinoma FGFR2 fusion PR −43.2 10.5 19 Cholangiocarcinoma FGFR2 I291, Y308 deletion PR −42.5 14.8 20 Cholangiocarcinoma FGFR2 fusion PR −34.1 11.2† 21 Cholangiocarcinoma FGFR2 fusion SD −42.2 2.5† 22 Cholangiocarcinoma FGFR2 Y375C mutation SD −37.5 3.7† 23 Cholangiocarcinoma FGFR2 W290C mutation SD −34.0 10.5 Urothelial tract/bladder cancer 24 Urothelial tract/bladder cancer FGFR3 Y373C mutation PR −50.8 6.2† 25 Urothelial tract/bladder cancer FGFR3 Y373C mutation SD −30.0 3.9 Other 26 Non-small cell lung cancer FGFR2 fusion SD −72.0 4.1 27 Prostate cancer FGFR2 fusion SD −32.5 6.4 BL, baseline; BOR, best overall response; CR, complete response; FGFR, fibroblast growth factor receptor; PFS, progression-free survival; PR, partial response; SD, stable disease. * Includes FGFR alterations confirmed through both local and central genetic testing reports. † Censored. Citation Format: Jordi Rodon, Silvia Damian, Muhammad Furqan, Jesus Garcia-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Lipika Goyal. Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT016." @default.
• W4365514100 created "2023-04-15" @default.
• W4365514100 creator A5001405370 @default.
• W4365514100 creator A5004741487 @default.
• W4365514100 creator A5015821261 @default.
• W4365514100 creator A5022526821 @default.
• W4365514100 creator A5031165814 @default.
• W4365514100 creator A5034689165 @default.
• W4365514100 creator A5048416014 @default.
• W4365514100 creator A5054141550 @default.
• W4365514100 creator A5058709133 @default.
• W4365514100 creator A5060631720 @default.
• W4365514100 creator A5060702411 @default.
• W4365514100 creator A5060949051 @default.
• W4365514100 creator A5081868383 @default.
• W4365514100 creator A5083477114 @default.
• W4365514100 date "2023-04-14" @default.
• W4365514100 modified "2023-10-01" @default.
• W4365514100 title "Abstract CT016: Clinical and translational findings of pemigatinib in previously treated solid tumors with activating <i>FGFR1-3</i> alterations in the FIGHT-207 study" @default.
• W4365514100 doi "https://doi.org/10.1158/1538-7445.am2023-ct016" @default.
• W4365514100 hasPublicationYear "2023" @default.
• W4365514100 type Work @default.
• W4365514100 citedByCount "0" @default.
• W4365514100 crossrefType "journal-article" @default.
• W4365514100 hasAuthorship W4365514100A5001405370 @default.
• W4365514100 hasAuthorship W4365514100A5004741487 @default.
• W4365514100 hasAuthorship W4365514100A5015821261 @default.
• W4365514100 hasAuthorship W4365514100A5022526821 @default.
• W4365514100 hasAuthorship W4365514100A5031165814 @default.
• W4365514100 hasAuthorship W4365514100A5034689165 @default.
• W4365514100 hasAuthorship W4365514100A5048416014 @default.
• W4365514100 hasAuthorship W4365514100A5054141550 @default.
• W4365514100 hasAuthorship W4365514100A5058709133 @default.
• W4365514100 hasAuthorship W4365514100A5060631720 @default.
• W4365514100 hasAuthorship W4365514100A5060702411 @default.
• W4365514100 hasAuthorship W4365514100A5060949051 @default.
• W4365514100 hasAuthorship W4365514100A5081868383 @default.
• W4365514100 hasAuthorship W4365514100A5083477114 @default.
• W4365514100 hasConcept C104317684 @default.
• W4365514100 hasConcept C121608353 @default.
• W4365514100 hasConcept C126322002 @default.
• W4365514100 hasConcept C143065580 @default.
• W4365514100 hasConcept C143998085 @default.
• W4365514100 hasConcept C170493617 @default.
• W4365514100 hasConcept C184235292 @default.
• W4365514100 hasConcept C2780210213 @default.
• W4365514100 hasConcept C32619005 @default.
• W4365514100 hasConcept C49418065 @default.
• W4365514100 hasConcept C502942594 @default.
• W4365514100 hasConcept C55493867 @default.
• W4365514100 hasConcept C71924100 @default.
• W4365514100 hasConcept C74373430 @default.
• W4365514100 hasConcept C82867764 @default.
• W4365514100 hasConcept C86803240 @default.
• W4365514100 hasConcept C95444343 @default.
• W4365514100 hasConceptScore W4365514100C104317684 @default.
• W4365514100 hasConceptScore W4365514100C121608353 @default.
• W4365514100 hasConceptScore W4365514100C126322002 @default.
• W4365514100 hasConceptScore W4365514100C143065580 @default.
• W4365514100 hasConceptScore W4365514100C143998085 @default.
• W4365514100 hasConceptScore W4365514100C170493617 @default.
• W4365514100 hasConceptScore W4365514100C184235292 @default.
• W4365514100 hasConceptScore W4365514100C2780210213 @default.
• W4365514100 hasConceptScore W4365514100C32619005 @default.
• W4365514100 hasConceptScore W4365514100C49418065 @default.
• W4365514100 hasConceptScore W4365514100C502942594 @default.
• W4365514100 hasConceptScore W4365514100C55493867 @default.
• W4365514100 hasConceptScore W4365514100C71924100 @default.
• W4365514100 hasConceptScore W4365514100C74373430 @default.
• W4365514100 hasConceptScore W4365514100C82867764 @default.
• W4365514100 hasConceptScore W4365514100C86803240 @default.
• W4365514100 hasConceptScore W4365514100C95444343 @default.
• W4365514100 hasIssue "8_Supplement" @default.
• W4365514100 hasLocation W43655141001 @default.
• W4365514100 hasOpenAccess W4365514100 @default.
• W4365514100 hasPrimaryLocation W43655141001 @default.
• W4365514100 hasRelatedWork W1986779513 @default.
• W4365514100 hasRelatedWork W1990357663 @default.
• W4365514100 hasRelatedWork W2043890160 @default.
• W4365514100 hasRelatedWork W2051893611 @default.
• W4365514100 hasRelatedWork W2190768709 @default.
• W4365514100 hasRelatedWork W2409987903 @default.
• W4365514100 hasRelatedWork W2529261610 @default.
• W4365514100 hasRelatedWork W2713333706 @default.
• W4365514100 hasRelatedWork W2764038087 @default.
• W4365514100 hasRelatedWork W2901585843 @default.
• W4365514100 hasVolume "83" @default.
• W4365514100 isParatext "false" @default.
• W4365514100 isRetracted "false" @default.
• W4365514100 workType "article" @default.